PMID-25331030 – Ipamorelin for Postoperative Ileus Phase II RCT
Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534.
Quick Reference
| Property | Value |
|---|---|
| PMID | 25331030 |
| DOI | 10.1007/s00384-014-2030-8 |
| Year | 2014 |
| Journal | International Journal of Colorectal Disease |
| Study Type | Phase II Randomized Controlled Trial |
| Evidence Level | II |
| Sample | n=114 patients undergoing bowel resection surgery |
| Peptide(s) Studied | Ipamorelin |
Key Findings
- Most important human clinical trial for ipamorelin to date
- n=114 bowel resection patients randomized to IV ipamorelin 0.03 mg/kg BID or placebo
- Median time to first meal was 25.3 hours in the ipamorelin group vs 32.6 hours in placebo (not statistically significant, p=0.15)
- Trend toward faster GI recovery with ipamorelin, though primary endpoint was not met
- Ipamorelin was safe and well-tolerated with no serious adverse events attributed to the study drug
- Adverse event profile was comparable between ipamorelin and placebo groups
- Secondary endpoints showed consistent trends favoring ipamorelin for GI recovery markers
Study Design
Multicenter, prospective, randomized, double-blind, placebo-controlled Phase II trial. Patients undergoing open or laparoscopic bowel resection were randomized 1:1 to receive IV ipamorelin 0.03 mg/kg or placebo BID starting postoperatively. Primary endpoint was time to first tolerated meal. Secondary endpoints included time to first flatus, first bowel movement, and hospital discharge. Safety was assessed by adverse event monitoring.
Limitations
- Study was powered as proof-of-concept, not for definitive efficacy — likely underpowered for the primary endpoint
- The p-value of 0.15 suggests a real effect may exist but the study lacked statistical power to detect it
- IV route used — does not inform about subcutaneous dosing commonly used in clinical peptide therapy
- Single dose level tested — higher or more frequent dosing may have been more effective
- Heterogeneous surgical population (open and laparoscopic, various bowel segments)
- Time to first meal is a partially subjective endpoint influenced by surgeon preference
Clinical Relevance
This is the most rigorous human clinical trial for ipamorelin and provides Level II evidence for its safety and tolerability. While the primary endpoint was not statistically significant, the 7.3-hour reduction in time to first meal is clinically meaningful for postoperative patients. The clean safety profile is the most important finding for practitioners — it provides human safety data that can be referenced when discussing ipamorelin use with patients. The GI prokinetic effect also supports ipamorelin's use beyond GH secretion, particularly in protocols where gut motility is a concern.
Related
#research #RCT #ipamorelin #evidence-level-II